News

The director of functional neurosurgery at Baptist Health provided perspective on the advances of high intensity focused ultrasound as the institution nears 100 patients treated. [WATCH TIME: 4 minutes]

The FDA is expected to make a decision by May 10, 2023, whether brexpiprazole will become the first approved therapy for Alzheimer disease agitation.

A derived Obstructive Sleep Apnea score of 2-3 and cumulative sleep symptoms were found to be associated with a significantly higher odds of acute stroke.

The chief medical officer of QurAlis talked about the potential of QRL-201 in patients with ALS from her talk presented at the 2023 MDA conference. [WATCH TIME: 4 minutes]

Findings from a recent published study observed lower quality of life in Black, Hispanic, and Asian patients with Parkinson disease compared with White patients.

In addition to high rates of individuals who required rescue therapy after midazolam, a substantial number of children needed respiratory support following.

The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 5 minutes]

In patients with high C-reactive protein levels treated with NP001, investigators observed a 64% slower rate of decline in forced vital capacity.

ARIA-inducing monoclonal antibodies accelerated ventricular enlargement to a point where a striking correlation between ventricular volume and ARIA frequency was observed.

The multicenter, multiple-ascending dose trial will feature 64 patients with ALS who will be assessed on safety and pharmacokinetic outcomes.

Evobrutinib, a highly selective BTK inhibitor, has previously demonstrated positive impacts on relapse rates and neurofilament light in patients with relapsing multiple sclerosis.

Episode 33 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University; and Clifton L. Gooch, MD, of the University of South Florida. [WATCH TIME: 9 minutes]

On average, across all levels of physical fatigue, participants would accept a 0.32 year decrease in time to multiple sclerosis progression in exchange for a 3.57-point change in FSIQ-RMS-S score.

The neuromuscular physician at Virginia Commonwealth University talked about the promising future of gene therapy and access to resources in Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on invasive procedures for degenerative conditions and when deep brain stimulation is needed.

Sitra Tauscher-Wisniewski, MD, vice president clinical development and analytics, Novartis Gene Therapies, talked about the new data findings from a study on gene therapy Zolgensma at the 2023 MDA conference.

The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on the advances of DBS and other invasive procedures for patients with degenerative disorders. [WATCH TIME: 4 minutes]

In the phase 2 study, patients with Guillian-Barré syndrome will receive imlifidase on day 1, followed with intravenous immunoglobulin on days 3-7, with outcomes of safety and change in disability.

At the 2023 MDA’s Clinical and Scientific conference, the neurology resident at Penn Medicine talked about the challenges of delivering intrathecal therapies and the importance of planning clinical resources for patients with ALS. [WATCH TIME: 3 minutes]

Compared with children without posttraumatic headache, those who experienced migraine symptoms following concussion were nearly 3 times more likely to report reliable increases in somatic symptoms.

At 2-year follow-up, 72% of patients with drug-resistant epilepsy who underwent surgery were seizure-free, compared with 33% of patients on standard medical therapy.

Positive phase 2 data on CVN424, NETSseq platforms, and CVN417, a novel treatment for Parkinson disease, were presented at AD/PD 2023 International Conference.

The immunology fellow at Brigham and Women’s Hospital discussed the current state of care for patients with MOGAD, and whether treatment decisions differ based on timing of attacks. [WATCH TIME: 7 minutes]

After 6 months of stimulation, more than half (53%) of patients with drug-resistant epilepsy were responders to treatment with at least a 50% reduction in seizure frequency.

The co-founder and chief executive officer of MyoGene Bio talked about the advantages of gene editing over traditional gene therapy as a long term treatment for neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Incidence of narcolepsy increased 4.17- and 1.42-fold during and after the 2009 H1N1 pandemic when compared with baseline.

The research physical therapist at Nationwide Children’s Hospital talked about the role of physical therapy in the changing landscape of care with neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 5 minutes]